Deciphera Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call and Webcast on March 9, 2020
- Wall Street ends sharply higher after Powell comments
- Salesforce (CRM) shares slide despite topping earnings, revenue expectations
- Fed's Powell: Rate hikes to slow, but adjustment just beginning
- Snowflake shares plunge 13% despite Q3 beat
- Market turmoil and economic decline, before recovery in 2023, says JPM's Kolanovic
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its fourth quarter and full year 2019 financial results on Monday, March 9, 2020.
In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Monday, March 9, 2020, to discuss the Company’s financial results and provide a general corporate update.
The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 1669368. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule product candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, and agents designed to inhibit reprogramming of cancer cell metabolism. We have used our platform to develop a diverse pipeline of tumor-targeted, immuno-targeted, and metabolism-targeted product candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.
Deciphera Pharmaceuticals, Inc.
Source: Deciphera Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Salesforce (CRM) Tops Q3 EPS by 18c, Offers Guidance
- Universal Robina Corporation Selects Blue Yonder to Digitally Transform Planning Capabilities
- Arco Announces Receipt of Non-Binding Going Private Proposal
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!